美罗培南治疗新生儿重症多重耐药菌感染临床研究
|
摘要
目的:探讨美罗培南治疗新生儿重症多重耐药菌感染的临床效果。方法:将62例2017年1月—2018年6月本院收治的重症多重耐药菌感染新生患儿随机分为研究组和对照组,每组31例。两组患儿入院后均接受常规治疗,对照组在常规治疗基础上采用头孢他啶进行治疗,研究组在常规治疗基础上采用美罗培南进行治疗。比较两组患儿的不良反应发生情况和治疗效果。结果:本研究选取的62例新生儿细菌培养结果均呈阳性,其中革兰氏阴性菌构成比为64.51%,革兰氏阳性菌、真菌构成比分别为24.20%、11.29%。研究组不良反应发生率(9.69%)低于对照组(35.49%),且组间差异明显(P<0.05)。研究组治疗总有效率(83.87%)高于对照组(61.29%),且组间差异明显(P<0.05)。结论:采用美罗培南治疗新生儿重症多重耐药菌感染疗效显著、不良反应少,具有较高的有效性和安全性。
Objective:To investigate the clinical effect of meropenem in the treatment of severe multidrug resistant bacteria infection in neonates.Methods:From January 2017 to June 2018,62 newborns with severe multidrug resistant bacteria infection were randomly divided into study group and control group with 31 cases in each group.The two groups received routine treatment after admission,the control group was treated with ceftazidime on the basis of routine treatment,and the study group was treated with meropenem on the basis of routine treatment.The incidence of adverse reactions and therapeutic effects were compared between the two groups.Results:The bacterial culture results of 62 newborns in this study were positive.The composition ratio of Gram-negative bacteria was 64.51%,Gram-positive bacteria and fungal composition ratio were 24.20%and 11.29%,respectively.The incidence of adverse reactions in the study group(9.69%) was lower than that in the control group(35.49%),and the difference between the two groups was signi?cant(P<0.05).The total effective rate in the study group(83.87%) was higher than that in the control group(61.29%),and the difference between the two groups was signi?cant(P<0.05).Conclusion:Meropenem is effective and safe in the treatment of severe multidrug resistant bacterial infections in neonates.
Objective:To investigate the clinical effect of meropenem in the treatment of severe multidrug resistant bacteria infection in neonates.Methods:From January 2017 to June 2018,62 newborns with severe multidrug resistant bacteria infection were randomly divided into study group and control group with 31 cases in each group.The two groups received routine treatment after admission,the control group was treated with ceftazidime on the basis of routine treatment,and the study group was treated with meropenem on the basis of routine treatment.The incidence of adverse reactions and therapeutic effects were compared between the two groups.Results:The bacterial culture results of 62 newborns in this study were positive.The composition ratio of Gram-negative bacteria was 64.51%,Gram-positive bacteria and fungal composition ratio were 24.20%and 11.29%,respectively.The incidence of adverse reactions in the study group(9.69%) was lower than that in the control group(35.49%),and the difference between the two groups was signi?cant(P<0.05).The total effective rate in the study group(83.87%) was higher than that in the control group(61.29%),and the difference between the two groups was signi?cant(P<0.05).Conclusion:Meropenem is effective and safe in the treatment of severe multidrug resistant bacterial infections in neonates.
引文
[1]新生儿重症监护病房早产儿产气肠杆菌医院感染及药敏分析[J].中国新生儿科杂志,2017,32(4):250-254.
[2]马荣伟,王莉.美罗培南治疗新生儿重症细菌感染的临床疗效及安全性分析[J].中国药物与临床,2016,16(10):1481-1482.
[3]重症监护病房患者美罗培南治疗药物监测队列研究[J].医药导报,2017,36(10):1190-1193.
[4]新生儿重症监护室患儿肠道内定植的大肠埃希菌和肠球菌耐药分析[J].中华流行病学杂志,2017,38(9):1259-1262.
[5]赵小利,连亚楠,李萌,等.多药耐药菌混合感染重症患者的个体化抗感染治疗研究[J].中华医院感染学杂志,2017,27(13):3002-3005.
[6]延时与间断输注美罗培南治疗重症感染患者的系统评价[J].中国医院药学杂志,2017,37(2):155-160.
[7]徐兰,唐祯,陈集志,等.美罗培南血清浓度测定及在重症感染患者中的临床应用[J].中南药学,2018,(2):238-242.
[8]王庞,王蕴.重症监护病房院内感染患者细菌种类及耐药性分析[J].安徽医学,2016,37(9):1133-1135.
[9]谢建宁,王兆莉,戴怡蘅,等.NICU多重耐药菌筛查及耐药性分析[J].中国妇幼保健,2016,31(22):4744-4746.
[10]谢伟,景春梅.2010-2015年重庆市某三甲儿童医院新生儿感染细菌的变迁及耐药性分析[J].中国感染与化疗杂志,2017,17(4):428-432.
[11]美罗培南与乌司他丁在重症感染患者治疗中的效果分析[J].中华医院感染学杂志,2016,26(8):1709-1711.
[12]冯靖雄,黄纯友,兰清,等.重症监护病房耐美罗培南铜绿假单胞菌感染的危险因素分析及干预对策[J].解放军医药杂志,2017,(10):93-96.
[2]马荣伟,王莉.美罗培南治疗新生儿重症细菌感染的临床疗效及安全性分析[J].中国药物与临床,2016,16(10):1481-1482.
[3]重症监护病房患者美罗培南治疗药物监测队列研究[J].医药导报,2017,36(10):1190-1193.
[4]新生儿重症监护室患儿肠道内定植的大肠埃希菌和肠球菌耐药分析[J].中华流行病学杂志,2017,38(9):1259-1262.
[5]赵小利,连亚楠,李萌,等.多药耐药菌混合感染重症患者的个体化抗感染治疗研究[J].中华医院感染学杂志,2017,27(13):3002-3005.
[6]延时与间断输注美罗培南治疗重症感染患者的系统评价[J].中国医院药学杂志,2017,37(2):155-160.
[7]徐兰,唐祯,陈集志,等.美罗培南血清浓度测定及在重症感染患者中的临床应用[J].中南药学,2018,(2):238-242.
[8]王庞,王蕴.重症监护病房院内感染患者细菌种类及耐药性分析[J].安徽医学,2016,37(9):1133-1135.
[9]谢建宁,王兆莉,戴怡蘅,等.NICU多重耐药菌筛查及耐药性分析[J].中国妇幼保健,2016,31(22):4744-4746.
[10]谢伟,景春梅.2010-2015年重庆市某三甲儿童医院新生儿感染细菌的变迁及耐药性分析[J].中国感染与化疗杂志,2017,17(4):428-432.
[11]美罗培南与乌司他丁在重症感染患者治疗中的效果分析[J].中华医院感染学杂志,2016,26(8):1709-1711.
[12]冯靖雄,黄纯友,兰清,等.重症监护病房耐美罗培南铜绿假单胞菌感染的危险因素分析及干预对策[J].解放军医药杂志,2017,(10):93-96.